RQ3013

RQ3013 is an mRNA-based COVID-19 vaccine developed to encode a chimeric spike protein containing mutations from both the Alpha (B.1.1.7) and Beta (B.1.351) variants of SARS-CoV-2, with some sources also indicating inclusion of Omicron variant mutations[5][6]. The vaccine uses pseudouridine-modified messenger RNA encapsulated in lipid nanoparticles to deliver the genetic instructions for spike protein expression, thereby inducing an immune response[1][2][5]. Preclinical studies demonstrated that RQ3013 elicits robust neutralizing antibody responses against multiple SARS-CoV-2 variants in animal models[4][6]. In clinical trials as a heterologous booster following three doses of inactivated vaccines, RQ3013 showed superior immunogenicity and acceptable safety compared to other boosters such as Ad5-nCoV and ZF2001, with relative efficacy against symptomatic infection ranging from 62% to 69%[1][2]. The vaccine is being developed by Walvax and RNAcure.

Other names

RQ3013RQ-3013RQ 3013